retatrutide benefits research vs Tirzepatide: Key Differences for Researchers Retatrutide Results: 28.3% Weight Loss
Description
The Economist, 2023
GLP-1 " "
Secondary outcomes included site-specific cancer risks stratified by GLP-1 agonist type and treatment duration
Yang HY, Liu M, Sheng Y, Zhu L, Jin MM, Jiang TX et al (2022) All-trans retinoic acid impairs glucose-stimulated insulin secretion by activating the RXR/SREBP-1c/UCP2 pathway
